Operator of a biotechnology company intended to develop immunological alteration therapies to prevent transplant rejection in patients. The company offers regulatory properties that are capable of controlling immune hyperactivation processes responsible for various serious diseases with high incidence in the population, enabling medical professionals to reduce the use of immunosuppressive drugs in pathologies and the side effects that their chronic use entails.
Telara Pharma focuses on developing a pharmaceutical drug aimed at treating and preventing acute kidney injury. The company's innovative approach involves a small molecule inhibitor targeting the dipeptidase-1 (DPEP-1) enzyme. This mechanism works by preventing the degradation of the imipenem antibiotic within the kidney, thereby reducing the risk of toxicity from other medications and decreasing the likelihood of kidney damage due to generalized infections. Through this development, Telara Pharma seeks to enhance patient outcomes in those at risk of acute kidney injury.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.